EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

IMB Dx, Inc (461030) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of IMB Dx, Inc KRW 1,509, price KRW 2,745, upside -45.0%, quality 38 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · KR

ID Thin data Sep 24, 2026

IMB Dx, Inc

461030 · KQ

Weakest SetupStrongly overvalued and low quality.

!Fair value 1,509 KRW · Strongly overvalued (−45%)
!Quality 38/100
!Expensive Growth (revenue 3y +26.6 %/yr)
!Loss-making · -150.1% net margin (TTM)
!negative free cash flow
!Trails peers (1/7)
!Narrow moat 12/100
!Evidence only low, so the estimate is less certain
Watch IMB Dx, Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

36,000 KRW 2,500 KRW Fair Value 1,509 KRW Apr 2024 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

30‑month range 2,500 KRW – 36,000 KRW · fair‑value band 996.12 KRW – 1,887 KRW · the 2,745 KRW price screens above the 1,509 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow IMB Dx in your weekly email

Every Wednesday you see whether IMB Dx is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

IMB Dx, Inc. provides liquid biopsy platform in South Korea.

Show more

IMB Dx, Inc. provides liquid biopsy platform in South Korea. It offers AlphaLiquid Platform that provides circulation-tumor DNA-based precision diagnostics solutions across various stages of cancer for patients, survivors, and individuals; AlphaLiquid HRR for diagnostics of targeted therapies, utilizing liquid biopsy profiling technology; and AlphaLiquid 100 test, a tool that enables the detection of biomarkers across 118 cancer-related genes through one blood test. The company also provides CancerDetect, a liquid biopsy platform for the early detection of cancer recurrence post-surgery; and CancerFind, a blood-based test for various cancer early detection. IMB Dx, Inc. was founded in 2018 and is based in Seoul, South Korea.

Stock analysis

IMB Dx, Inc (461030) currently trades at 2,745 KRW, while our model-based Fair Value estimate is 1,509 KRW, implying the stock looks roughly 81.9% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: 996.12 KRW (bear) to 1,887 KRW (bull), the price of 2,745 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 38/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

IMB Dx, Inc reported revenue of 5.3B KRW in FY2025 versus 1.2B KRW in FY2021, a compound +44.3%/yr. Reported net income was −7.9B KRW in FY2025.

Key figures

Market cap 43.2B KRW (≈ $31.8M) · P/S ratio 7.72 · Net margin −149% · Return on equity −30.6% · Return on assets (EBIT) −42.8% · Operating margin −193% · Revenue (TTM) 5.6B KRW · Revenue growth (YoY) +27.1%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).

What moves the price

The share trades about 77% below its 52-week high and 10% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −45%, 461030 screens richer than that median.

Fair Value models

Bear 996.12 KRW Fair Value 1,509 KRW Bull 1,887 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) 877.76 KRW 1,176 KRW 1,756 KRW 51
All 1 models by family
Asset-Based
NCAV (Graham) 877.76 KRW 1,176 KRW 1,756 KRW 51

Open the full fair value analysis →

Notify me when 461030 reaches fair value

Put 461030 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 38/100

Of which business quality 41 · Market factors (momentum, volatility) 18

Profitability 3
Margins and returns on capital today
Quality Growth 72
Are margins and returns improving?
Cashflow 6
Earnings quality: real cash, not paper profit
Fin. Strength 81
Balance sheet, leverage, solvency risk
Investment 13
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 7
Price trend over the last 3–12 months (market factor)
52W Momentum 1
Distance to the 52-week high (market factor)
Net Issuance 81
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 38/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+56.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+26.6%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−429.0% (2021) → −162.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

461030 screens 82% overvalued. Compare with Thermo Fisher Scientific Inc →

Compare IMB Dx, Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 143 stocks

Beats the industry median on 1/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 41 · Below median
Fair Value upside −45% · Below median
Profitability
Return on assets −19% · Bottom 25%
Net margin (TTM) −150% · Bottom 25%
Operating margin (TTM) −193% · Bottom 25%
Growth and dividend
Revenue growth 27% · Top 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 28
PAST (return on equity)0 · sector 8
HEALTH (low debt)0 · sector 95
DIVIDEND (yield)0 · sector 30

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Thermo Fisher Scientific Inc TMO $678.39 $686.04 +1%
Danaher Corporation DHR $223.77 $209.18 −7%
WuXi AppTec Co 2359 HK$207.60 HK$228.36 +10%
Lonza Group LONN CHF 570.00 CHF 151.69 −73%
IDEXX Laboratories, Inc IDXX $522.02 $495.84 −5%
Agilent Technologies, Inc A $165.32 $63.90 −61%
Waters Corporation WAT $425.74 $106.31 −75%
IQVIA Holdings IQV $270.09 $295.80 +10%
Illumina, Inc ILMN $255.38 $280.92 +10%
Mettler-Toledo International Inc MTD $1,491 $635.75 −57%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

IMB Dx, Inc · Fair Value
1,509 KRW −82%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "IMB Dx, Inc Fair Value". https://www.fairvalue-calculator.com/stock/461030

Frequently asked questions

Is IMB Dx, Inc (461030) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 1,509 KRW versus a price of 2,745 KRW, about −45% upside (overvalued).
What is the fair value of 461030?
Our model-based fair value for IMB Dx, Inc is 1,509 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 2,745 KRW.
What is the quality score of 461030?
IMB Dx, Inc has a Quality Score of 38/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for IMB Dx, Inc (461030)?
Our model-based price target is the fair value of 1,509 KRW (as of Sep 24, 2026) from 1 valuation models. Cautious scenario 996.12 KRW, optimistic scenario 1,887 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the IMB Dx, Inc stock forecast for 2026?
Our models put fair value at 1,509 KRW, about −45% upside versus a price of 2,745 KRW (overvalued). Cautious scenario 996.12 KRW, optimistic scenario 1,887 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of IMB Dx, Inc (461030)?
IMB Dx, Inc reported trailing-twelve-month revenue of about 5.6B KRW (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of IMB Dx, Inc (461030)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For IMB Dx, Inc it is 1,509 KRW per share (as of Sep 24, 2026), against a price of 2,745 KRW. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is IMB Dx, Inc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 461030 trades above its calculated fair value: price 2,745 KRW, fair value 1,509 KRW, a gap of about −45% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 461030?
No. The price is what the market pays today (2,745 KRW); the fair value is what the company's own numbers justify (1,509 KRW). For IMB Dx, Inc the two are 1,236 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is IMB Dx, Inc worth?
The market values IMB Dx, Inc at about 43.2B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 2,745 KRW; our models calculate a fair value of 1,509 KRW per share.
What do the bullish and bearish scenarios say about 461030?
Our models span a range for IMB Dx, Inc: cautious scenario 996.12 KRW, base 1,509 KRW, optimistic 1,887 KRW per share (as of Sep 24, 2026, price 2,745 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of IMB Dx, Inc (461030)?
Balance-sheet figures for IMB Dx, Inc (as of Sep 24, 2026): return on equity −30.6%. They feed the Quality Score of 38/100, which measures business quality independently of the share price.
How far is 461030 from its 52-week high?
IMB Dx, Inc trades at 2,745 KRW, about 77% below its 52-week high of 12,080 KRW and 10% above the low of 2,500 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 1,509 KRW is for.
Which stocks are comparable to IMB Dx, Inc?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is IMB Dx, Inc stock attractive at the current price?
The data as of Sep 24, 2026: price 2,745 KRW, calculated fair value 1,509 KRW (−45%), Quality Score 38/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 461030 calculated?
We run IMB Dx, Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 1,509 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. IMB Dx, Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of IMB Dx, Inc (461030)?
The closing price on Sep 23, 2026 was 2,745 KRW. Our model-based fair value is 1,509 KRW, about −45% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with IMB Dx, Inc right now?
The price sits above even our optimistic bull case (1,887 KRW). The favourable scenario is already priced in. Weak quality (38/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (996.12 KRW to 1,887 KRW) leaves room in how you read the outcome.

Key figures of IMB Dx, Inc

How large is the market capitalisation of IMB Dx, Inc (461030)?
The market capitalisation of IMB Dx, Inc is 43.2B KRW (≈ $31.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of IMB Dx, Inc (461030)?
The price-to-sales ratio of IMB Dx, Inc is 7.72 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of IMB Dx, Inc (461030)?
The net margin of IMB Dx, Inc is −149% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of IMB Dx, Inc (461030)?
The return on equity (ROE) of IMB Dx, Inc is −30.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of IMB Dx, Inc (461030)?
On an EBIT basis the return on assets of IMB Dx, Inc is −42.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of IMB Dx, Inc (461030)?
The operating margin of IMB Dx, Inc is −193% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at IMB Dx, Inc (461030)?
Revenue at IMB Dx, Inc is growing +27.1% versus a year earlier (3y avg +26.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does IMB Dx, Inc (461030) generate?
The free cash flow of IMB Dx, Inc is −7.2B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch IMB Dx, Inc in the live analysis

One click puts IMB Dx, Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.